{
    "clinical_study": {
        "@rank": "65584", 
        "arm_group": [
            {
                "arm_group_label": "Normal Renal Function", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Mild Renal Impairment", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Moderate Renal Impairment", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Severe Renal Impairment", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "Since the amount of palbociclib eliminated in urine is 6.9%, renal impairment is not\n      expected to have much impact on palbociclib. However,  the Federal Drug Administration (FDA)\n      Guidance recommends a study in subjects with renal impairment when the drug is likely to be\n      used in patients with impaired renal function.  Palbociclib is intended for chronic use in\n      cancer patients who may have some degree of impaired renal function."
        }, 
        "brief_title": "Study Of Palbociclib In Renal Impairment", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Renal Impairment", 
        "condition_browse": {
            "mesh_term": "Renal Insufficiency"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Personally signed and dated informed consent document.\n\n          -  Renal function calculated by the Cockcroft Gault equation: normal function (CLcr >=90\n             mL/min),  mild:  CLcr >=60 mL/min and <90 mL/min, moderate:  CLcr >=30 mL/min and <60\n             mL/min, severe:  CLcr <30 mL/min but not requiring hemodialysis.\n\n          -  Subjects with normal renal function matched for age, weight, gender and race to\n             subjects in impaired renal function groups.\n\n        Exclusion Criteria:\n\n          -  Any condition possibly affecting drug absorption.\n\n          -  Renal allograft recipients."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "28", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 11, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02085538", 
            "org_study_id": "A5481014"
        }, 
        "intervention": [
            {
                "arm_group_label": "Normal Renal Function", 
                "description": "palbociclib 125 mg oral capsule with food once", 
                "intervention_name": "palbociclib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Mild Renal Impairment", 
                "description": "palbociclib 125 mg oral capsule with food once", 
                "intervention_name": "palbociclib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Moderate Renal Impairment", 
                "description": "palbociclib 125 mg oral capsule with food once", 
                "intervention_name": "palbociclib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Severe Renal Impairment", 
                "description": "palbociclib 125 mg oral capsule with food once", 
                "intervention_name": "palbociclib", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "renal impairment", 
            "AUC", 
            "Cmax", 
            "palbociclib", 
            "normal matched subjects"
        ], 
        "lastchanged_date": "May 22, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A5481014&StudyName=Study%20Of%20Palbociclib%20In%20Renal%20Impairment"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "DeLand", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32720"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32809"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saint Paul", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55114"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 1, Open-Label, Single Dose, Parallel-Group Study To Evaluate The Pharmacokinetics Of Palbociclib (PD-0332991) In Subjects With Impaired Renal Function", 
        "overall_contact": {
            "last_name": "Pfizer CT.gov Call Center", 
            "phone": "1-800-718-1021"
        }, 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "AUC (0 - 8)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - 8). It is obtained from AUC (0 - t) plus AUC (t - 8).", 
                "measure": "Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)]", 
                "safety_issue": "No", 
                "time_frame": "8 days"
            }, 
            {
                "measure": "Maximum Observed Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "8 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02085538"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)", 
                "measure": "Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)", 
                "safety_issue": "No", 
                "time_frame": "8 days"
            }, 
            {
                "description": "Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.  Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling.  Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.", 
                "measure": "Apparent Oral Clearance (CL/F)", 
                "safety_issue": "No", 
                "time_frame": "8 days"
            }, 
            {
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "8 days"
            }, 
            {
                "description": "Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.", 
                "measure": "Apparent Volume of Distribution (Vz/F)", 
                "safety_issue": "No", 
                "time_frame": "8 days"
            }, 
            {
                "description": "Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.", 
                "measure": "Plasma Decay Half-Life (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "8 days"
            }, 
            {
                "description": "Clearance of unbound drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the oral bioavailability. Unbound drug clearance is a quantitative measure of the rate at which an unbound drug substance is removed from the blood.", 
                "measure": "Unbound Apparent Oral Clearance (CLu/F)", 
                "safety_issue": "No", 
                "time_frame": "8 days"
            }, 
            {
                "description": "AUC (0 - \u221e)u= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - \u221e)u for unbound drug. It is obtained from AUC (0 - t)u plus AUC (t - \u221e)u for unbound drug.", 
                "measure": "\"Unbound Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - \u221e)u]\"", 
                "safety_issue": "No", 
                "time_frame": "8 days"
            }, 
            {
                "description": "Cmaxu is the highest measured unbound plasma concentration during the dosing interval.", 
                "measure": "Unbound Maximum Observed Plasma Concentration (Cmaxu)", 
                "safety_issue": "No", 
                "time_frame": "8 days"
            }, 
            {
                "description": "Area under the plasma concentration time-curve from zero to the last measured concentration (AUClastu) for unbound drug.", 
                "measure": "\"Unbound Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClastu)\"", 
                "safety_issue": "No", 
                "time_frame": "8 days"
            }, 
            {
                "description": "fraction of drug in plasma or tissues that is not bound to plasma or tissue proteins.", 
                "measure": "fraction of unbound drug in plasma (fu)", 
                "safety_issue": "No", 
                "time_frame": "8 days"
            }, 
            {
                "description": "Unbound Volume of distribution is defined as the theoretical volume in which the total unbound amount of drug would need to be uniformly distributed to produce the desired unbound plasma concentration of a drug. Unbound Apparent volume of distribution after oral dose (Vzu/F) is influenced by the fraction absorbed.", 
                "measure": "Unbound Apparent Volume of Distribution (Vzu/F)", 
                "safety_issue": "No", 
                "time_frame": "8 days"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}